FGFR2 and neoplasm: Two of the four patients whose primary tumors showed FGFR2 amplification on single-spot TMA but had non-corresponding FGFR2-amplified clones in their metastases showed identical results even on whole tumor blocks, and vice versa for the tumors that had only FGFR2-amplified clones in the metastases.